Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study

Table 1

Characteristics of the patients and treatments.

Group characteristics	First group (1)	Second group (2)
	Standard GVHD prophylaxis	Standard GVHD prophylaxis + MMSCs
Sex of patient, male/female	7/11	8/11
Median age, years (range)	29 (19–60)	34 (20–63)
Diagnosis, n
AML/MDS	10	14
ALL	4	2
CML	3	3
CLL	1
Disease stage, n
complete remission	15	19
non-complete remission	3	0
Conditioning regimen, n
RIC	4	6
MAC	14	13
Observation time, months	3.5–30.5	2.5–32

AML: acute myeloid leukemia, MDS: myelodysplastic syndrome, ALL: acute lymphoid leukemia, CML: chronic myeloid leukemia, CLL: chronic lymphoid leukemia, RIC: reduced intensity conditioning, MAC: myeloablative conditioning.